Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers
Source abstract
Abstract
Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand 97178, Iran
Department of Bioengineering, University of Pennsylvania, 210 South 33rd Street, Philadelphia, Pennsylvania 19104, United States
Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
Department of Orthopedics, University Medical Center Utrecht, 3584 Utrecht, The Netherlands
Regenerative Medicine Center Utrecht, University Medical Center Utrecht, 3584 Utrecht, The Netherlands
Funding
National Center for Advancing Translational Sciences · National Science Foundation Graduate Research Fellowship Program · National Cancer Institute · National GEM Consortium · Division of Chemical, Bioengineering, Environmental, and Transport Systems · Burroughs Wellcome Fund · Fontaine Society, University of Pennsylvania
References (100+)
Show source-provided references
1. 10.1038/nrc359910.1038/nrc3599 ↗
2. 10.1038/s41586-019-1730-110.1038/s41586-019-1730-1 ↗
3. 10.1038/s41467-020-19505-210.1038/s41467-020-19505-2 ↗
4. 10.1038/s41392-020-0207-x10.1038/s41392-020-0207-x ↗
5. 10.1016/j.gene.2019.14407110.1016/j.gene.2019.144071 ↗
6. 10.1021/acs.molpharmaceut.2c0081110.1021/acs.molpharmaceut.2c00811 ↗
7. 10.1038/s43586-022-00104-y10.1038/s43586-022-00104-y ↗
8. 10.1021/acsomega.2c0784010.1021/acsomega.2c07840 ↗
9. 10.1016/j.lfs.2021.11933710.1016/j.lfs.2021.119337 ↗
10. 10.1016/j.nantod.2012.06.01310.1016/j.nantod.2012.06.013 ↗
11. 10.1016/j.jconrel.2014.09.00110.1016/j.jconrel.2014.09.001 ↗
12. 10.1016/j.trsl.2019.07.00610.1016/j.trsl.2019.07.006 ↗
13. 10.1155/2013/78204110.1155/2013/782041 ↗
14. 10.1016/j.nwnano.2023.10000610.1016/j.nwnano.2023.100006 ↗
15. 10.1080/17435889.2024.237706210.1080/17435889.2024.2377062 ↗
16. 10.1038/3588810.1038/35888 ↗
17. 10.1038/s41573-019-0017-410.1038/s41573-019-0017-4 ↗
18. 10.1002/cmdc.20090044410.1002/cmdc.200900444 ↗
19. Sioud M. · 2021 · 1
20. 10.1038/sj.onc.120801010.1038/sj.onc.1208010 ↗
21. 10.1038/nm.215810.1038/nm.2158 ↗
22. 10.1038/s42003-022-04389-310.1038/s42003-022-04389-3 ↗
23. 10.1016/j.cell.2009.05.00610.1016/j.cell.2009.05.006 ↗
24. 10.1038/cgt.2013.810.1038/cgt.2013.8 ↗
25. 10.1038/s41598-021-00085-010.1038/s41598-021-00085-0 ↗
26. 10.1038/nbt.154710.1038/nbt.1547 ↗
27. 10.1038/nm112710.1038/nm1127 ↗
28. 10.1038/sj.cgt.770093110.1038/sj.cgt.7700931 ↗
29. 10.1038/nbt93610.1038/nbt936 ↗
30. Tong A. W. · Curr. Opin. Mol. Ther. · 2005 · 7 · 114
31. 10.1002/med.2024410.1002/med.20244 ↗
32. 10.1038/nbt.380210.1038/nbt.3802 ↗
33. 10.1038/nature0230210.1038/nature02302 ↗
34. 10.1021/mp900093r10.1021/mp900093r ↗
35. 10.1038/nchembio83910.1038/nchembio839 ↗
36. 10.1016/j.tips.2009.04.00910.1016/j.tips.2009.04.009 ↗
37. Li C. · 2022 · 18110.1007/978-981-16-5419-0_4 ↗
38. 10.1038/nrd301010.1038/nrd3010 ↗
39. 10.1038/nrc296610.1038/nrc2966 ↗
40. 10.1038/sj.onc.120673310.1038/sj.onc.1206733 ↗
41. 10.1038/nrg214110.1038/nrg2141 ↗
42. 10.1038/s41576-021-00439-410.1038/s41576-021-00439-4 ↗
43. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
44. 10.1016/j.bbadis.2023.16672010.1016/j.bbadis.2023.166720 ↗
45. 10.1016/j.jconrel.2022.05.03510.1016/j.jconrel.2022.05.035 ↗
46. 10.1016/j.semcancer.2022.01.00810.1016/j.semcancer.2022.01.008 ↗
47. 10.1038/s44222-024-00154-910.1038/s44222-024-00154-9 ↗
48. 10.1038/s41578-022-00529-710.1038/s41578-022-00529-7 ↗
49. 10.1038/s41392-023-01642-x10.1038/s41392-023-01642-x ↗
50. Greish K. · 2010 · 2510.1007/978-1-60761-609-2_3 ↗
51. 10.1021/nn304406610.1021/nn3044066 ↗
52. 10.1016/j.biomaterials.2015.11.02510.1016/j.biomaterials.2015.11.025 ↗
53. 10.1038/s41565-023-01498-w10.1038/s41565-023-01498-w ↗
54. 10.1152/physrev.00015.201610.1152/physrev.00015.2016 ↗
55. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
56. 10.1021/acsnano.8b0774610.1021/acsnano.8b07746 ↗
57. 10.1016/j.biomaterials.2013.04.06010.1016/j.biomaterials.2013.04.060 ↗
58. 10.1021/acsnano.2c0454310.1021/acsnano.2c04543 ↗
59. 10.1038/s44222-024-00192-310.1038/s44222-024-00192-3 ↗
60. 10.1016/j.ijpharm.2019.11862810.1016/j.ijpharm.2019.118628 ↗
61. 10.1021/acs.accounts.9b0022810.1021/acs.accounts.9b00228 ↗
62. 10.2217/nnm.15.8610.2217/nnm.15.86 ↗
63. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
64. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
65. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
66. 10.1021/acsnano.7b0721410.1021/acsnano.7b07214 ↗
67. 10.1021/jacs.0c0902910.1021/jacs.0c09029 ↗
68. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
69. 10.1021/nn900002m10.1021/nn900002m ↗
70. 10.1007/s00432-014-1767-310.1007/s00432-014-1767-3 ↗
71. 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
72. 10.1016/j.addr.2016.06.01110.1016/j.addr.2016.06.011 ↗
73. 10.1016/j.jconrel.2010.01.03610.1016/j.jconrel.2010.01.036 ↗
74. 10.1021/acs.jmedchem.9b0051110.1021/acs.jmedchem.9b00511 ↗
75. 10.1016/j.jconrel.2020.01.03510.1016/j.jconrel.2020.01.035 ↗
76. 10.1007/s10875-010-9468-410.1007/s10875-010-9468-4 ↗
77. 10.1002/smll.20080071410.1002/smll.200800714 ↗
78. 10.3389/fimmu.2017.0128710.3389/fimmu.2017.01287 ↗
79. 10.1021/acs.molpharmaceut.7b0105510.1021/acs.molpharmaceut.7b01055 ↗
80. 10.1021/nn901877h10.1021/nn901877h ↗
81. 10.1038/nrd.2016.19910.1038/nrd.2016.199 ↗
82. 10.3389/fphar.2021.80330410.3389/fphar.2021.803304 ↗
83. 10.1016/j.jconrel.2021.10.02810.1016/j.jconrel.2021.10.028 ↗
84. 10.1016/j.jddst.2023.10456210.1016/j.jddst.2023.104562 ↗
85. 10.1038/nrc72710.1038/nrc727 ↗
86. 10.1016/j.ejpb.2010.06.01110.1016/j.ejpb.2010.06.011 ↗
87. 10.1093/nar/gnh14010.1093/nar/gnh140 ↗
88. 10.1021/mp300273310.1021/mp3002733 ↗
89. 10.1016/j.drudis.2021.11.01110.1016/j.drudis.2021.11.011 ↗
90. 10.1021/acsomega.0c0584810.1021/acsomega.0c05848 ↗
91. 10.1021/acs.biomac.5b0118910.1021/acs.biomac.5b01189 ↗
92. 10.1021/bc400226b10.1021/bc400226b ↗
93. 10.1021/acs.bioconjchem.8b0077810.1021/acs.bioconjchem.8b00778 ↗
94. 10.1021/acsami.8b1305910.1021/acsami.8b13059 ↗
95. 10.3389/fbioe.2023.117715110.3389/fbioe.2023.1177151 ↗
96. 10.1021/cr100353t10.1021/cr100353t ↗
97. 10.1021/acs.accounts.7b0031810.1021/acs.accounts.7b00318 ↗
98. 10.1002/med.2198110.1002/med.21981 ↗
99. 10.1039/C4RA05092D10.1039/C4RA05092D ↗
100. 10.1126/sciadv.adg829210.1126/sciadv.adg8292 ↗